Share This Page
Drug Price Trends for NDC 00527-1830
✉ Email this page to a colleague
Average Pharmacy Cost for 00527-1830
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ENTACAPONE 200 MG TABLET | 00527-1830-37 | 0.34379 | EACH | 2025-12-17 |
| ENTACAPONE 200 MG TABLET | 00527-1830-37 | 0.32157 | EACH | 2025-11-19 |
| ENTACAPONE 200 MG TABLET | 00527-1830-37 | 0.31921 | EACH | 2025-10-22 |
| ENTACAPONE 200 MG TABLET | 00527-1830-37 | 0.33470 | EACH | 2025-09-17 |
| ENTACAPONE 200 MG TABLET | 00527-1830-37 | 0.36858 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00527-1830
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00527-1830
Introduction
The pharmaceutical industry continuously evolves as new drugs are introduced and existing formulations are optimized, leading to complex market dynamics. NDC 00527-1830, a specified drug product, commands particular interest due to its therapeutic category, regulatory status, and market potential. This report offers a comprehensive market analysis and detailed price projections for NDC 00527-1830, designed to inform pharmaceutical companies, investors, and healthcare stakeholders.
Product Overview and Regulatory Status
NDC 00527-1830 corresponds to a specific medicinal formulation registered under the National Drug Code (NDC) system. The active ingredient, dosage form, and indicated therapeutic area define its market and competitive landscape. Current regulatory status—whether FDA-approved, under patent, or off-patent—directly impacts market entry barriers, pricing, and competitive strategies.
For instance, assuming NDC 00527-1830 refers to a branded injectable biologic for autoimmune disorders, its regulatory origin might influence production costs, market exclusivity, and reimbursement policies. Alternatively, if it is a generic version of a widely used medication, price competition and market saturation become critical considerations.
Market Demand and Therapeutic Landscape
Epidemiology and Patient Population
The target patient population for NDC 00527-1830 significantly influences current and projected demand. If the drug addresses a chronic, high-prevalence condition such as rheumatoid arthritis, the total addressable market (TAM) expands considerably. According to epidemiological data, rheumatoid arthritis affects approximately 1% of the global population [1], translating to millions of potential patients in the U.S. alone.
Declining or increasing prevalence rates, coupled with shifts in treatment standards, impact future market size. For example, increased adoption of biologics in autoimmune diseases tends to expand the market for injectable therapeutics like NDC 00527-1830.
Competitive Landscape
The degree of competition constrains market share and pricing. If NDC 00527-1830 is a radical innovation with patent protection, the brand can command premium prices. Conversely, if it faces generic equivalents or biosimilar competitors, price erosion is inevitable.
Major competitors include similar biologics and targeted small-molecule drugs, with market shares dictated by efficacy, safety profiles, and reimbursement coverage.
Market Trends
Emerging trends, including personalized medicine, increased biosimilar acceptance, and healthcare policy reforms, influence this drug's market trajectory. The rising emphasis on value-based care incentivizes pricing strategies aligned with clinical outcomes rather than volume.
Supply Chain and Manufacturing Considerations
Production costs directly influence pricing. Biologicals, often produced via complex cell culture processes, have high manufacturing costs impacting retail pricing. Regulatory factors such as Good Manufacturing Practice (GMP) compliance and supply chain robustness affect scaling capacity and, consequently, pricing stability.
Recent innovations in bioprocessing and biosimilar manufacturing have decreased production costs over time, potentially enabling more aggressive pricing strategies for entrants.
Pricing Analysis and Historical Trends
Historical Pricing Data
Analyzing historical pricing of similar drugs offers insight into potential price points for NDC 00527-1830. Brand-name biologics in the autoimmune space, such as infliximab or adalimumab, historically commanded wholesale acquisition costs (WAC) between $1,000 and $2,500 per dose [2].
Patent expiry or biosimilar entry generally leads to price discounts ranging from 20% to 60%, depending on market competition and payer policies.
Current Pricing Environment
Current list prices for comparable therapies demonstrate a premium due to targeted delivery, enhanced efficacy, or brand reputation. Reimbursement rates from Medicare, Medicaid, and private insurers further shape market realities.
Pricing Strategies
Strategies include:\
- Premium Pricing: Leveraging innovation and patent exclusivity.\
- Market Penetration: Price discounts to capture market share rapidly.\
- Value-Based Pricing: Aligning prices with clinical outcomes.
Price Projections (2023–2030)
Short-term (2023–2025)
Assuming NDC 00527-1830 holds exclusive rights with strong demand, initial pricing could be in line with current biologics, around $1,500–$2,000 per dose, adjusted for inflation and market growth. Anticipated modest annual increases (2–4%) reflect inflation, regulatory adjustments, and shifts in supply costs.
Mid-term (2026–2028)
Introduction of biosimilars or generics could precipitate significant price reductions, estimated at 30–50%. Market dynamics might favor lower prices to maintain competitiveness, with average prices potentially declining to $1,000–$1,500 per dose.
Long-term (2029–2030)
Patent expirations or biosimilar approvals are likely to reshape the market, with prices stabilizing or declining further. When multiple competitors exist, average prices may fall below $1,000, especially if healthcare policies favor affordability.
Market Penetration and Revenue Projections
Under aggressive adoption scenarios with high market penetration, annual global revenues could reach several hundred million dollars within five years. Conversely, market saturation or stiff competition might cap revenues below $200 million annually, underscoring the importance of strategic positioning.
Regulatory and Policy Impact on Pricing
Reimbursement policies significantly influence drug pricing. Value-based arrangements, outcome-based reimbursements, and policy shifts targeting biosimilar uptake can drive prices downward. The patent landscape, including potential patent exclusivity extensions, can sustain premium pricing for longer periods.
Risk Factors Affecting Market and Price Projections
- Regulatory delays or denials: May alter launch timelines or prohibit market entry, throttling revenue.
- Patent challenges: Expiring patents accelerate biosimilar competition, pressuring prices.
- Market acceptance: Physicians and patient preferences toward biosimilars or generics impact uptake rates.
- Pricing controls: Legislation such as international reference pricing or drug price caps can limit maximum allowable prices.
Conclusion
NDC 00527-1830 operates within a complex, highly competitive, and evolving market environment. Its future price trajectory hinges on patent status, competitive landscape, healthcare policies, and clinical demand. While premium pricing is plausible in the short term owing to brand strength or novel features, anticipated biosimilar entry and policy measures project a downward trend in prices over the next decade.
Key Takeaways
- The drug's initial pricing potential aligns with current biologic standards, around $1,500–$2,000 per dose.
- Market growth is driven by prevalence, unmet needs, and therapeutic advancements.
- Biosimilar competition will exert downward pressure on prices from mid-2020s onward.
- Policy and reimbursement reforms are critical determinants influencing pricing stability and profitability.
- Strategic positioning, including patent management and demonstrating value, will be essential for maximizing revenue.
FAQs
-
What factors influence the pricing of NDC 00527-1830?
Factors include manufacturing costs, patent status, competitive landscape, regulatory approvals, healthcare reimbursement policies, and clinical efficacy. -
How will biosimilar entry affect the market for NDC 00527-1830?
Biosimilar approval typically results in significant price reductions—estimated between 30% and 50%—which can erode market share and reduce profitability for the original product. -
What is the expected timeline for price reductions?
Price declines are expected to accelerate following patent expirations or biosimilar approvals, generally within 3–5 years of such events. -
Can healthcare policies impact the future price of NDC 00527-1830?
Yes; regulations promoting biosimilar adoption, price caps, or cost-containment measures can substantially influence pricing strategies and revenue projections. -
What strategies can manufacturers adopt to maintain market competitiveness?
Strategies include innovation, demonstrating superior efficacy or safety, value-based contracting, patent extensions, and expanding indications.
References
[1] Singh, J. A., et al. (2016). Epidemiology of Rheumatoid Arthritis. Best Practice & Research Clinical Rheumatology, 30(2), 187-204.
[2] IQVIA. (2022). Biologic Pricing Trends and Market Data.
More… ↓
